Reports Q1 revenue $30.5M, consensus $27.1M. “We are proud to start the year with another record quarter, delivering $30.5 million in net sales, a 38% year-over-year growth fueled by both Tru Niagen(R) and strong Niagen(R) ingredient demand, a 63.4% gross margin, and $5.1 million in net income,” said Niagen Bioscience (NAGE) CEO Rob Fried. “With strong momentum heading into 2025, and with the launch of our new brand identity and expansion of our NAD+ precursor patent portfolio, we are reinforcing a powerful foundation for the future of healthy aging and are energized by the market’s growing trust in Niagen.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- CDXC Earnings this Week: How Will it Perform?
- Niagen Bioscience: Strategic Positioning and Clinical Advancements Drive Buy Rating
- Niagen confirms operations remain resilient amid new tariff developments
- Niagen Bioscience’s Strategic Rebranding and Promising Clinical Developments Drive Buy Rating
- Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent